Page last updated: 2024-09-05

erlotinib hydrochloride and Cough

erlotinib hydrochloride has been researched along with Cough in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hebisawa, A; Hirose, T; Kitani, M; Kusaka, K; Matsui, H; Miyakawa, K; Ohta, K; Shimada, M; Tamura, A; Yokoyama, A	1
Cadranel, J; Cong, XJ; Fairclough, D; Finnern, HW; Hirsh, V; Lorence, RM; Miller, VA; Palmer, M; Yang, JC	1
Ayoub, J; Bezjak, A; Chan, RT; Clark, G; Cyjon, A; de Albuquerque Ribeiro, R; Fenton, D; Gerogianni, A; Laberge, F; Lago, S; Noble, J; Reck, M; Seymour, L; Shepherd, FA; Trajkovic, A; Tu, D; von Pawel, J; Zukin, M	1

Trials

2 trial(s) available for erlotinib hydrochloride and Cough

Article	Year
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:2 Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Fatigue; Female; Follow-Up Studies; Gefitinib; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Prognosis; Quality of Life; Quinazolines; Salvage Therapy	2013
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24 Topics: Adult; Aged; Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Pain; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires; Survival Analysis; Treatment Outcome	2006

Article

Year

Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:2

Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Fatigue; Female; Follow-Up Studies; Gefitinib; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Prognosis; Quality of Life; Quinazolines; Salvage Therapy

2013

Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24

Topics: Adult; Aged; Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Pain; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires; Survival Analysis; Treatment Outcome

2006

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Cough

Article	Year
Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib. Internal medicine (Tokyo, Japan), 2018, Aug-15, Volume: 57, Issue:16 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adrenal Cortex Hormones; Anaplastic Lymphoma Kinase; Carbazoles; Cough; ErbB Receptors; Erlotinib Hydrochloride; Female; Fever; Humans; Hypoxia; Lung Neoplasms; Middle Aged; Mutation; Piperidines; Receptor Protein-Tyrosine Kinases; Treatment Outcome	2018

Article

Year

Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib.

Internal medicine (Tokyo, Japan), 2018, Aug-15, Volume: 57, Issue:16

Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adrenal Cortex Hormones; Anaplastic Lymphoma Kinase; Carbazoles; Cough; ErbB Receptors; Erlotinib Hydrochloride; Female; Fever; Humans; Hypoxia; Lung Neoplasms; Middle Aged; Mutation; Piperidines; Receptor Protein-Tyrosine Kinases; Treatment Outcome

2018